TABLE 2.
Opportunities to optimize antimicrobials based on the BCID-GN panel result
| Opportunity to optimize antimicrobials | Total | Change | Sensitivity/PPA |
Specificity/NPA |
||
|---|---|---|---|---|---|---|
| No. of TP/no. of TP+FN | % (95% CI) | No. of TN/no. of TN+FP | % (95% CI) | |||
| CTX-M (5 E. coli, 3 K. pneumoniae isolates)a | 8 | Optimize | 8/8 | 100 (63.0–100) | 97/97 | 100 (96.3–100) |
| OXA23/48 (A. baumannii) | 1 | Escalate | 1/1 | 100 (2.5–100) | 104/104 | 100 (96.5–100) |
| S. maltophilia | 1 | TMP/SMX | NAb | NA | NA | NA |
| Total | 10 | 9.3% (10/108) of tests yielded potentially clinically actionable results | ||||
a
Consistent with alternative resistance mechanisms, only 8/12 (66.7%) Enterobacterales isolates with resistance to third-generation cephalosporins harbored the CTX-M gene.
b
NA, not available.